RedHill Biopharma Ltd Announces New U.S. Patent for RedHill's Talicia for H.pyloriAccesswire • 10/12/21
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034PRNewsWire • 10/12/21
RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization RequirementsPRNewsWire • 10/06/21
RedHill Biopharma reports 62% mortality reduction in moderately severe COVID-19 patients treated with oral opaganib in new analysis of data from global Phase 2/3 studyProactive Investors • 10/04/21
RedHill's stock is up 7.0% as it shares new data about experimental COVID-19 drugMarket Watch • 10/04/21
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 PatientsAccesswire • 10/04/21
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with AurobindoPRNewsWire • 09/23/21
RedHill Biopharma accelerates US Phase 2/3 COVID-19 study of once-daily oral RHB-107 in non-hospitalized patients with South African approvalProactive Investors • 09/14/21
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 PatientsPRNewsWire • 09/14/21
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African ApprovalPRNewsWire • 09/13/21
